When announcing the signing of the protocol of intent on scientific collaboration and exchange of material and knowledge, INMI Health Director Francesco Vaia confirmed the intention of developing a specific project on the possibility of using mixtures of vaccines in the prevention of the disease.
In this regard, he expressed confidence in obtaining clearance from the Italian Medicines Agency (AIFA) to develop a study related to the administration of the second dose to patients who received the first shot from Anglo-Swedish AstraZeneca drugmaker.
The media reported that 600 volunteers will take part in the test, who will be administered variants Ad5 and Ad26 of Sputnik V and vaccines produced by the Pfizer/BioNTech and Moderna companies as a second shot.
rly/aph/mem/fgg